|Synthetic Biologics Comes With Initial Data Validating Platform Expansion|
|By Marilyn Mullen|
|Wednesday, 03 June 2015 18:36|
Synthetic Biologics Inc. (NYSEMKT:SYN) came out with the initial data supporting the firm’s development of a platform of therapeutics made for protecting microbiome from carbapenems, a series of beta-lactam antibiotics.This data was given at 115 General Meeting of American Society of Microbiology (ASM) in New Orleans, LA.
Beta-lactam antibiotics are the mainstay in hospital infection management. But, antibiotics have potential of resulting in unwanted perilous effects within gastrointestinal tract including disruption of natural balance of gut microbiome which causes 1.1 million C. difficile infections as well as 30,000 C. difficile-related deaths in United States every year.
SYN-004 is the firm’s candidate therapy made for degrading some intravenous beta-lactam antibiotics within GI tract as well as maintaining natural balance of gut microbiome for preventing C. difficile infection, secondary antibiotic-resistant infection as well as antibiotic-associated diarrhea.
Jeffrey Riley, Chief Executive Officer of Synthetic Biologics, opined that the firm continues to make intellectual property portfolio for covering expansion of beta-lactamase platform focusing on protecting gut microbiome for preventing C. difficile infection as well as antibiotic-associated diarrhea.
Successful clinical development can increase clinician acceptance of product line after commercialization.
Synthetic Biologics also came out with Clinical Evaluation of SYN-004, an Oral Beta-Lactamase Therapy for preventing Antibiotic-Induced Disruption of Intestinal Microflora that summarized Phase 1 clinical data aiding SYN-004 program.
Some of the conclusions from Phase 1a (40 participants) and Phase 1b (24 participants) clinical trials of SYN-004. This showed that it had single dose of up to 750mg along with multiple doses of 300mg four times a day for seven days.
Shares of SYN are up 4.40% to $2.38.